Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 3 2025 07 21 248 260 I Made Adi Narendranatha Komara Department of Internal Medicine, Faculty of Medicine, Udayana University/Central General Hospital Prof. Dr. I.G.N.G Ngoerah Denpasar, Bali, Indonesia Ketut Suega Medical Hemato-Oncology Division, Department of Internal Medicine, Faculty of Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia Ni Made Renny Anggreni Rena Medical Hemato-Oncology Division, Department of Internal Medicine, Faculty of Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia I Wayan Losen Adnyana Medical Hemato-Oncology Division, Department of Internal Medicine, Faculty of Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia 2024 08 08 2024 12 18 Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. This study aims to conduct a five-year update on induction chemotherapy's efficacy, safety, and prognostic value in patients with AML. Based on the PRISMA 2020 guidelines, a systematic search was performed on online databases for relevant studies on complete remission with incomplete hematologic response (CRi), complete remission (CR), adverse events, and overall survival. The articles obtained were observational studies that met the inclusion and exclusion criteria. The quality of the studies was assessed using the Revised Cochrane’s risk-of-bias tool. The analysis was conducted using Review Manager 5.4 and R Statistical Software 3.3. Thirteen clinical trial studies, involving 1,863 participants, were included in this survey. Based on the analysis, the CRi and CR levels, where each was obtained as a whole at 9% (random effect; 95%CI 6-13%; heterogeneity; https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2294 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2294/1091